Copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2001
Our analysis was a model of the costs and benefits of universal newborn hearing screening compared with targeted screening. The short-term, direct costs were compared with the expected number of cases of significant, bilateral congenital deafness detected and with the expected number of false-positive screening results. Such modeling is important because few high-quality data are available.
In the discussion of our analysis we neither advocated universal screening nor refuted the potential benefit of adopting universal screening. Instead, we focused on ways to maximize the benefits of universal screening, such as ensuring follow-up for children with abnormal screening results, prospectively studying treatment efficacy, and developing strategies to ameliorate the harms of false-positive screening.
Kemper AR. Universal Newborn Hearing Screening—Reply. Arch Pediatr Adolesc Med. 2001;155(3):422. doi:10.1001/archpedi.155.3.417